
USD
$0.00
(0.00%
)At Close (As of Dec 12, 2025)
$41.59M
Market Cap
-
P/E Ratio
-4.68
EPS
$10.07
52 Week High
$1.70
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$51M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $662K |
| Capital Expenditures | $52K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | $16M |
| Cashflow From Financing | $116M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$53M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
OnKure Therapeutics, Inc. is a pioneering biopharmaceutical company based in Boulder, Colorado, focused on advancing precision oncology solutions to address critical unmet needs in cancer treatment. Leveraging state-of-the-art drug discovery platforms, OnKure is dedicated to developing targeted therapies that exemplify its commitment to personalized medicine. With a robust pipeline of innovative therapeutic candidates, the company is well-positioned to significantly improve patient outcomes and transform the oncology landscape.